“This move in Alnylam is crazy. I cannot believe what I’m seeing on my screen.”
That’s the text I received from a health care investor, who is long on Alnylam Pharmaceuticals (ALNY), when I asked him late Wednesday to explain the stock’s incredible 52 percent jump on the positive patisiran APOLLO study results announced hours earlier.
About the Author Reprints
